ATEM (Alvesco Non-interventional Study)

AstraZeneca

Status: Completed

Conditions: Asthma; Allergy

Treatments: Drug: Alvesco

Study type: Observational

Funder types: Industry

Identifiers

NCT01147224

CL-9709-401-DE

Details and patient eligibility

About

The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

• Asthma with or without allergic components

Main Exclusion Criteria:

• Hypersensitive to compounds of Alvesco
• Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3

Trial design

400 participants in 1 patient group

ATEM

Description:

A prospective one-arm non-interventional study with asthma patients treated with Alvesco.

Treatment:

Drug: Alvesco